Methods:The patients with multiple myeloma received a joint chemotherapy containing VELCADE.
方法:多发性骨髓瘤患者接受含有万珂的联合方案进行化疗。
参考来源 - 万珂在治疗多发性骨髓瘤中的临床应用·2,447,543篇论文数据，部分数据来源于NoteExpress
Compared to traditional chemotherapy, what is the advantage of Velcade?
您认为含万珂的化疗方案与传统方案相比，有什么优势？
Reconstituted VELCADE should be administered within 8 hours of preparation.
重新配制的万珂应当在制备后8个小时内使用。
Bortezonib (velcade) is the first proteasome inhibitor that has entered clinical trial.
波替单抗(万珂)是第一个进入临床试验的蛋白酶体抑制剂。
应用推荐